MGO Private Wealth LLC Invests $287,000 in Danaher Co. (NYSE:DHR)

MGO Private Wealth LLC purchased a new stake in Danaher Co. (NYSE:DHR) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,149 shares of the conglomerate’s stock, valued at approximately $287,000.

Other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares during the last quarter. Capital International Investors grew its holdings in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares during the period. Norges Bank acquired a new stake in Danaher in the fourth quarter worth $1,752,382,000. Finally, Franklin Resources Inc. boosted its position in shares of Danaher by 6.4% during the fourth quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock worth $1,531,510,000 after purchasing an additional 395,498 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

DHR stock traded down $5.38 during trading hours on Monday, reaching $244.47. The stock had a trading volume of 3,205,009 shares, compared to its average volume of 2,852,813. The stock has a market capitalization of $181.08 billion, a PE ratio of 42.31, a price-to-earnings-growth ratio of 3.82 and a beta of 0.84. The stock has a 50-day simple moving average of $255.96 and a 200 day simple moving average of $246.75. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter last year, the company posted $2.36 earnings per share. Danaher’s quarterly revenue was down 2.6% on a year-over-year basis. Analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is 18.31%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the sale, the senior vice president now owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock valued at $37,536,717 over the last ninety days. 10.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on DHR shares. Bank of America upped their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Robert W. Baird boosted their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Finally, Jefferies Financial Group started coverage on shares of Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target for the company. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.